BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27350004)

  • 1. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4].
    Dietlein M; Eschner W; Grünwald F; Lassmann M; Verburg FA; Luster M
    Nuklearmedizin; 2016 Jun; 55(3):77-89. PubMed ID: 27350004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline].
    Dietlein M; Grünwald F; Schmidt M; Schneider P; Verburg FA; Luster M
    Nuklearmedizin; 2016 Dec; 55(6):213-220. PubMed ID: 27922153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
    Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
    Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
    Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Moser E; Reiners C; Schicha H; Schober O; ;
    Nuklearmedizin; 2007; 46(5):213-9. PubMed ID: 17938757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Procedural guideline for Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (version 5)].
    Verburg FA; Schmidt M; Kreissl MC; Grünwald F; Lassmann M; Hänscheid H; Hohberg M; Luster M; Dietlein M
    Nuklearmedizin; 2019 Jun; 58(3):228-241. PubMed ID: 31035298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for radioiodine therapy of differentiated thyroid cancer.
    Luster M; Clarke SE; Dietlein M; Lassmann M; Lind P; Oyen WJ; Tennvall J; Bombardieri E;
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1941-59. PubMed ID: 18670773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].
    Dietlein M; Dressler J; Farahati J; Grünwald F; Leisner B; Moser E; Reiners C; Schicha H; Schober O;
    Nuklearmedizin; 2004 Aug; 43(4):115-20. PubMed ID: 15316577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of bone metastases with radium-223. German guidelines].
    Pöppel TD; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Scheidhauer K; Schenck M; Sonnenschein W; Gabriel M
    Nuklearmedizin; 2016 Sep; 55(5):177-86. PubMed ID: 27417067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guideline for Radioiodine Therapy for Benign Thyroid Diseases (6/2022 - AWMF No. 031-003)].
    Dietlein M; Grünwald F; Schmidt M; Kreissl MC; Luster M; ; ; ;
    Nuklearmedizin; 2024 Feb; 63(1):8-20. PubMed ID: 37871629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
    Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
    Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.
    Clarke SE
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):430-7. PubMed ID: 20537878
    [No Abstract]   [Full Text] [Related]  

  • 12. [Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma].
    Verburg FA; Grünwald F; Lassmann M; Hänscheid H; Luster M; Dietlein M
    Nuklearmedizin; 2018 Aug; 57(4):124-136. PubMed ID: 30125925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
    Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
    N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I therapy of thyroid cancer patients.
    Reiners C; Farahati J
    Q J Nucl Med; 1999 Dec; 43(4):324-35. PubMed ID: 10731783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?
    Verburg FA; Luster M; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):183-184. PubMed ID: 27726016
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
    Luster M; Hänscheid H; Freudenberg LS; Verburg FA
    J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer].
    Dietlein M; Dressler J; Farahati J; Leisner B; Moser E; Reiners C; Schicha H; Schober O
    Nuklearmedizin; 1999; 38(6A):221-2. PubMed ID: 10510812
    [No Abstract]   [Full Text] [Related]  

  • 20. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.